Impact Biomedical (IBO) Change in Receivables (2025 - 2026)

Impact Biomedical's (IBO) quarterly Change in Receivables came in at -$5000.0 in Q1 2026, up 50.0% quarter-over-quarter from -$10000.0 in Q4 2025.

Analysis

Impact Biomedical (IBO) Change in Receivables (2025 - 2026) Analysis & Trends

Impact Biomedical (IBO) has reported Change in Receivables for 2 consecutive years, with -$5000.0 the latest figure, recorded in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn	1.09 Bn
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn	333.00 Mn
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn	140.20 Mn
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn	838.50 Mn
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn	-
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn	-53.00 Mn
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn	31.60 Mn
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn	269.40 Mn
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn	-
10	Impact Biomedical	49.63 Mn	49.62 Mn	2,000.00	-

Historic Data

Download Data